PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

CodeSystem: Risk Factors

Official URL: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp Version: 1.0.0
Active as of 2025-10-16 Computable Name: CsRiskFactorPcsp

Risk Factors used by the PCSP algorithm

This Code system is referenced in the content logical definition of the following value sets:

This case-sensitive code system http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp defines the following codes:

CodeDisplayDefinition
1.1 RT to a vol exposing the thyroid gland RT to a vol exposing the thyroid gland
1.2 TBI TBI
1.3 MIBG therapy (I-131 MIBG therapy) MIBG therapy (I-131 MIBG therapy)
2.1 RT >= 10 Gy to a vol exposing the breasts RT >= 10 Gy to a vol exposing the breasts
2.2 OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age
3.1 RT >= 35 Gy to a vol exposing the heart RT >= 35 Gy to a vol exposing the heart
3.2 Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
3.3 RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2 RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2
4.1 Alkylating agents Alkylating agents
4.2 RT to a vol exposing the testes RT to a vol exposing the testes
4.3 Including TBI Including TBI
5.1 RT >=12 Gy to a vol exposing the testicles RT >=12 Gy to a vol exposing the testicles
6.3 Surgery to the spinal cord, sympathetic nerves or pelvis Surgery to the spinal cord, sympathetic nerves or pelvis
6.4 Hypogonadal Hypogonadal
7.2 RT to a vol exposing the ovaries RT to a vol exposing the ovaries
8.1 RT >= 30 Gy to a vol exposing the head or the brain RT >= 30 Gy to a vol exposing the head or the brain
8.2 Cisplatin (with or without carboplatin > 1500 mg/m2) Cisplatin (with or without carboplatin > 1500 mg/m2)
9.1 RT to a vol exposing the pancreas RT to a vol exposing the pancreas
10.2 HSCT HSCT
11.1 RT to a volume exposing the hypothalamus or pituatary gland RT to a volume exposing the hypothalamus or pituatary gland
11.3 Hypothalamic or pituitary tumour Hypothalamic or pituitary tumour
11.4 Neurosurgery of the hypothalamus or pituitary gland Neurosurgery of the hypothalamus or pituitary gland
12.1 RT to a vol exposing the kidneys, heart and associated large vessels RT to a vol exposing the kidneys, heart and associated large vessels
12.3 Nephrectomy Nephrectomy
12.4 Ifosfamide Ifosfamide
12.5 Platinium based chemotherapy Platinium based chemotherapy
12.6 Nitrosureas Nitrosureas
12.7 Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously) Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)
13.1 Cranial and/or spinal RT Cranial and/or spinal RT
13.3 Methotrexate Methotrexate
13.4 Gonadal failure Gonadal failure
13.5 Growth hormone deficiency Growth hormone deficiency
13.6 Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment
13.7 HSCT, especially with an history of GVHD HSCT, especially with an history of GVHD
14.3 High dose RT High dose RT
15.1 Radiotherapy to a vol exposing the HP region >= 30 Gy Radiotherapy to a vol exposing the HP region >= 30 Gy
15.2 Surgery near or within the HP region Surgery near or within the HP region
15.3 CNS tumours near or within the HP region CNS tumours near or within the HP region
16.1 Radiotherapy to a vol exposing the HP region< 30 Gy Radiotherapy to a vol exposing the HP region< 30 Gy
16.2 Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD) Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)
17.1 Radiotherapy to a vol exposing the HP region Radiotherapy to a vol exposing the HP region
17.5 hydrocephalus or cerebrospinal fluid shunt hydrocephalus or cerebrospinal fluid shunt
19.3 Radioiodine therapy (I-131 ablation therapy) Radioiodine therapy (I-131 ablation therapy)
19.5 Allogenic HSCT Allogenic HSCT
19.6 Total thyroidectomy Total thyroidectomy
20.1 RT to a vol exposing the head, brain or neck RT to a vol exposing the head, brain or neck
21.1 History of a central nervous system tumor History of a central nervous system tumor
21.2 RT to a vol exposing the brain ANY DOSE RT to a vol exposing the brain ANY DOSE
21.4 Brain surgery Brain surgery
21.5 High dose cytarabine IV (intravenous) High dose cytarabine IV (intravenous)
21.6 High dose MTX IV High dose MTX IV
21.7 Any Chemotherapy IT (intrathecal) Any Chemotherapy IT (intrathecal)
22.1 Vinca-Alkaloids Vinca-Alkaloids
22.2 Cisplatin or carboplatin Cisplatin or carboplatin
23.1 RT to a vol exposing the lens RT to a vol exposing the lens
24.1 RT to a vol exposing the eye and orbit RT to a vol exposing the eye and orbit
25.1 RT to a vol exposing the craniofacial area, especially after high doses and at a young age RT to a vol exposing the craniofacial area, especially after high doses and at a young age
25.3 Surgery to the face, especially at a young age Surgery to the face, especially at a young age
26.1 Surgery of the spine Surgery of the spine
26.2 Surgery of the chest (Does not include CVC pose) Surgery of the chest (Does not include CVC pose)
26.3 RT to a vol exposing the spine RT to a vol exposing the spine
26.4 Spinal or paraspinal malignancies Spinal or paraspinal malignancies
27.1 Cyclophosphamide Cyclophosphamide
27.3 RT to a vol exposing the bladder RT to a vol exposing the bladder
27.5 Cystectomy Cystectomy
27.6 Hysterectomy Hysterectomy
27.7 Pelvic surgery Pelvic surgery
27.8 Spinal cord surgery Spinal cord surgery
28.1 RT to a vol exposing the uterus only female RT to a vol exposing the uterus only female
29.1 RT to a vol exposing the oral cavity or salivary glands RT to a vol exposing the oral cavity or salivary glands
29.4 Chemotherapy Chemotherapy
30.1 RT to a vol exposing the gastro-intestinal tract RT to a vol exposing the gastro-intestinal tract
30.3 Oesophageal surgery Oesophageal surgery
30.4 Abdominal surgery Abdominal surgery
30.5 With a history of chronic GVHD With a history of chronic GVHD
31.1 Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2 Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2
32.1 RT to a vol exposing the lungs RT to a vol exposing the lungs
32.3 Bleomycin Bleomycin
32.4 Busulfan Busulfan
32.5 BCNU Carmustine BCNU Carmustine
32.6 CCNU Lomustine CCNU Lomustine
32.7 Thoracic surgery Thoracic surgery
33.1 Cisplatin Any dose Cisplatin Any dose
33.2 Ifosfamide Any dose Ifosfamide Any dose
33.3 Carboplatin Any dose Carboplatin Any dose
34.1 RT to a volume exposing the liver RT to a volume exposing the liver
34.10 Chronic GVHD Chronic GVHD
34.11 Liver surgery Liver surgery
34.3 HSCT (irrespective of GVHD) HSCT (irrespective of GVHD)
34.5 Mercaptopurine Thioguanine Mercaptopurine Thioguanine
34.6 Dactinomycin Dactinomycin
34.8 Chronic viral hepatitis Chronic viral hepatitis
34.9 Sinusoidal obstruction syndrome Sinusoidal obstruction syndrome
35.1 HSCT (irrespective of GVHD) HSCT (irrespective of GVHD)
35.2 Multiple red blood cell transfusions Multiple red blood cell transfusions
36.1 Splenectomy Splenectomy
36.2 RT >= 10 Gy to a vol exposing the spleen RT >= 10 Gy to a vol exposing the spleen
36.3 Allogenic HSCT (with or without TBI) Allogenic HSCT (with or without TBI)
36.4 Autologus HSCT conditioned with TBI Autologus HSCT conditioned with TBI
37.1 Hereditary cancer sd Hereditary cancer sd
38.1 Any RT including TBI (predominantly in the RT field) Any RT including TBI (predominantly in the RT field)
38.2 HSCT Especially with a history of skin GvHD HSCT Especially with a history of skin GvHD
39.1 RT to a vol exposing the colon and rectum RT to a vol exposing the colon and rectum
40.1 RT to a vol exposing the oral cavity RT to a vol exposing the oral cavity
41.2 Anthracyclines and/or Mitoxantrone Anthracyclines and/or Mitoxantrone
41.3 Epipodophyllotoxins or autologous Epipodophyllotoxins or autologous
41.4 Autologous haematopoietic stem cell transplant Autologous haematopoietic stem cell transplant
42.1 Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis) Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)
45.1 RT to a vol exposing the head or brain RT to a vol exposing the head or brain
46.1 RT between 15 and 35 Gy to a vol exposing the heart RT between 15 and 35 Gy to a vol exposing the heart
46.2 Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2 Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2
47.1 RT to a vol exposing the kidney or urinary tract RT to a vol exposing the kidney or urinary tract